Review Article
Adjuvant Chemoradiation Therapy in Gastric Cancer: Critically Reviewing the Past and Visualizing the Next Step Forward
Table 1
Trials of curative strategy for gastric cancer.
| Trial | Patients number | Intervention | OS | DFS |
| INT-0116 | A: 275 B: 281 | A: Surgery B: Surgery→CRT | HR = 1.32; | HR = 1.51; |
| CALGB-80101 | A: 272 B: 274 | A: Surgery→CRT B: Surgery→ECF/CRT/ECF | HR = 1.03; | HR = 1; |
| ARTIST | A: 228 B: 230 | A: Surgery→XP B: Surgery→XP/CRT/XP | NR | HR = 0.687; |
| MAGIC | A: 253 B: 250 | A: Surgery B: ECF→Surgery→ECF | HR = 0.75; | HR = 0.66; |
| ACTS-GC | A: 530 B: 529 | A: Surgery B: Surgery→S-1 | HR = 0.68; | HR = 0.62; |
| CLASSIC | A: 515 B: 520 | A: Surgery B: Surgery→CAPOX | HR = 0.72; | HR = 0.75; |
| SAMIT | A: 359 B: 364 C: 355 D: 355 | A: Surgery→UFT B: Surgery→S-1 C: Surgery→Pac/UFT D: Surgery→Pac/S-1 | NR | (i) C + D versus A + B, HR = 0.92; (ii) A + C versus B + D, HR = 1.23; NR |
|
|
CRT: chemoradiation. ECF: epirubicin/cisplatin/5-fluorouracil. NR: not reported. XP: cisplatin/capecitabine. CAPOX: oxaliplatin/capecitabine.
|